Securing a Balanced Portfolio of PPI and P-CAB Products
In the first half of this year, Daewoong Bio successively launched two products: the proton pump inhibitor (PPI) formulation "Daewoong Rabeprazole Tab. 5mg" and the potassium-competitive acid blocker (P-CAB) formulation "Wecap Tab. 10mg." Wecap is a delegated generic version of Daewoong Pharmaceutical's 34th new drug, Fexuclu.
PPIs are the most commonly used first-line drugs in the GERD treatment market. According to the pharmaceutical market research agency UBIST, as of 2024, the prescription performance of single-agent PPI products reached 654.9 billion KRW. P-CABs are next-generation treatments that address the shortcomings of PPIs, such as slow onset of action, dietary effects, and drug-drug interactions.
Launched in March, Daewoong Rabeprazole Tab. is the first low-dose (5mg) generic among rabeprazole formulations. Its indications include GERD and gastric and duodenal ulcers. Notably, the insurance price for Daewoong Rabeprazole Tab. is 338 KRW per tablet, which is lower than the original drug Pariet Tab. (Eisai Korea) at 356 KRW.
Furthermore, in April, Fexuclu (10mg) received health insurance reimbursement for gastritis indications. As a result, Daewoong Bio launched the P-CAB class treatment "Wecap Tab. 10mg," further diversifying its GERD treatment lineup.
A Daewoong Bio representative stated, "By securing a balanced portfolio of PPI and P-CAB products in the GERD treatment market, we will provide a wide range of treatment options for healthcare professionals and patients. Moving forward, we will further strengthen Daewoong Bio's position in the field of gastrointestinal therapeutics."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
